Syra Health (SYRA) Q4 2025 earnings summary

Executive summary

• Achieved 157% year-over-year growth in Population Health revenue, reaching $5.3 million in FY2025.

• Net loss reduced by 76% to $(896K) in FY2025 from $(3.8M) in FY2024.

• EPS improved to $(0.08) from $(0.50) year-over-year, with Q4 EPS at $(0.01) versus $(0.08) in Q4 2024.

• Operating expenses declined 37% to $3.4 million, reflecting cost restructuring.

• Revenue for FY2025 was $7.2 million, a 9% decrease due to reduced federal funding.

Financial highlights

• Gross margin increased to 34.4% in FY2025 from 20.7% in FY2024, a 14% improvement.

• Adjusted EBITDA improved to $(863K) from $(3.7M) year-over-year.

• Cash on hand was $1.6 million with no long-term debt at year-end 2025.

• Q4 2025 net loss reduced 73% to $(135K) from $(504K) in Q4 2024.

Outlook and guidance

• Targeting profitability by year-end 2026, driven by demand for population health solutions and disciplined cost management.

• Positioned to benefit from new contract wins and participation in national healthcare initiatives.